Nebivolol: a novel beta-blocker with nitric oxide-induced vasodilatation
R Weiss - Vascular health and Risk management, 2006 - Taylor & Francis
Nebivolol is a novel beta1-blocker with a greater degree of selectivity for beta1-adrenergic
receptors than other agents in this class and a nitric oxide (NO)-potentiating, vasodilatory …
receptors than other agents in this class and a nitric oxide (NO)-potentiating, vasodilatory …
[HTML][HTML] Nebivolol: vasodilator properties and evidence for relevance in treatment of cardiovascular disease
JG Howlett - Canadian Journal of Cardiology, 2014 - Elsevier
Abstract β-adrenergic blocking agents, a pharmacologically diverse class of cardiovascular
medications, are recommended as first-line treatment for patients with hypertension and …
medications, are recommended as first-line treatment for patients with hypertension and …
Both morning and evening dosing of nebivolol reduces trough mean blood pressure surge in hypertensive patients
MC Acelajado, R Pisoni, T Dudenbostel… - Journal of the American …, 2012 - Elsevier
The morning blood pressure surge (MBPS) has been shown to be an independent predictor
of cardiovascular events. There is insufficient evidence on the effect of nebivolol, a …
of cardiovascular events. There is insufficient evidence on the effect of nebivolol, a …
Comparison of a new vasodilating β-blocker, carvedilol, with atenolol in the treatment of mild to moderate essential hypertension
LM Ruilope - American journal of hypertension, 1994 - academic.oup.com
Carvedilol is a new cardiovascular compound with the combined pharmacologic properties
of nonselective β-blockade and vasodilation. The aim of this study was to compare the safety …
of nonselective β-blockade and vasodilation. The aim of this study was to compare the safety …
Nebivolol: a review
J Cockcroft - Expert opinion on pharmacotherapy, 2004 - Taylor & Francis
Nebivolol is a vasodilating β-blocker, which can be distinguished from other β-blockers by its
haemodynamic profile. It combines β-adrenergic blocking activity with a vasodilating effect …
haemodynamic profile. It combines β-adrenergic blocking activity with a vasodilating effect …
[HTML][HTML] Rationale for nebivolol/valsartan combination for hypertension: review of preclinical and clinical data
TD Giles, JR Cockcroft, B Pitt, A Jakate… - Journal of …, 2017 - journals.lww.com
To treat hypertension, combining two or more antihypertensive drugs from different classes
is often necessary. β-Blockers and renin–angiotensin–aldosterone system inhibitors, when …
is often necessary. β-Blockers and renin–angiotensin–aldosterone system inhibitors, when …
Cost-effectiveness analysis of nebivolol and metoprolol in essential hypertension: a pharmacoeconomic comparison of antihypertensive efficacy of beta blockers
RS Patel, KH Sharma, NA Kamath… - Indian Journal of …, 2014 - journals.lww.com
Objective: To estimate and compare the cost-effectiveness and safety of nebivolol with
sustained-release metoprolol in reducing blood pressure by 1 mm of Hg per day in …
sustained-release metoprolol in reducing blood pressure by 1 mm of Hg per day in …
Metabolic profile of nebivolol, a β-adrenoceptor antagonist with unique characteristics
Abstract β-Adrenoceptor antagonists (β-blockers) have historically been considered an
effective and safe option for first-line treatment of hypertension. However, very recently, it …
effective and safe option for first-line treatment of hypertension. However, very recently, it …
Pharmacological properties of nebivolol in man
LV Bortel, J Hoon, MJF Kool, JAG Wijnen… - European journal of …, 1997 - Springer
Objectives The aims of the present study were to determine (1) the β 1-blocking potency and
(2) the β 1 adrenoceptor selectivity of nebivolol in man after repeated dosing (7 days) …
(2) the β 1 adrenoceptor selectivity of nebivolol in man after repeated dosing (7 days) …
Comparative Effects of a New Cardioselective Beta‐Blocker Nebivolol and Nifedipine Sustained‐Release on 24‐Hour Ambulatory Blood Pressure and Plasma …
Y Lacourcière, L Poirier, J Lefebvre… - The Journal of …, 1992 - Wiley Online Library
This double‐blind, parallel‐group study compared the effects of Nebivolol, a novel
cardioselective β‐blocker, with those of nifedipine sustained‐release on 24‐hour …
cardioselective β‐blocker, with those of nifedipine sustained‐release on 24‐hour …